Background-Oxidized LDLs (oxLDLs) and matrix metalloproteinases (MMPs) are present in atherosclerotic lesions.
A therogenesis is a progressive process characterized by the accumulation of lipids and fibrous elements in the wall of large arteries. [1] [2] [3] Smooth muscle cell (SMC) migration, proliferation, and secretion of extracellular matrix play a major role in the formation of the fibroproliferative plaques. The fibrous cap contributes to plaque stability but also favors the development of occlusive lesions or restenosis. [1] [2] [3] [4] LDLs are thought to become atherogenic after undergoing oxidative modifications. 5 Oxidized LDLs (oxLDLs), present in atherosclerotic lesions, may induce changes in lipoprotein metabolism, gene expression (of adhesion molecules, growth factors, and cytokines), cell viability/apoptosis, migration, and proliferation. [2] [3] [4] [5] [6] OxLDL-induced SMC proliferation involves various signaling pathways, 7 including the sphingomyelin/ceramide/ sphingosine-1-phosphate (Spm/Cer/S1P) pathway (which mediates DNA synthesis) 8 and the epidermal growth factor receptor (EGFR)/PI3K/Akt pathway (which mediates cell survival). 9 Matrix metalloproteinases (MMPs) are a broad family of zinc proteases, which participate in extracellular matrix turnover and vascular wall remodeling, angiogenesis, and atherosclerosis. 10 -13 MMPs are regulated by gene expression and activation of latent proenzymes by cleavage of the N-terminal prosegment. 10, 14 This partial proteolysis is mediated by various serine proteases, such as plasmin or thrombin, 11 or by cell surface-associated MMPs, such as membrane type 1 (MT-1)-MMP. 12 MMP activity is inhibited by specific natural tissue MMP inhibitors (TIMPs) 14 and by selective chemical inhibitors such as batimastat. 15 Because MMP activity is increased in atherosclerotic lesions, it has been hypothesized that MMPs may be involved in atherosclerotic processes, such as infiltration of inflammatory cells, SMC migration and proliferation, and plaque disruption. [11] [12] [13] Ox-LDLs and inflammatory cytokines, including interleukin-1 and tumor necrosis factor-␣, alter the expression and activity of MMPs and TIMPs. 11 For instance, oxLDLs enhance the expression and secretion of MMP-1 (interstitial collagenase) and MT1-MMP (activator of proMMP-2) in endothelial cells and that of MMP-9 (gelatinase B) in SMCs. 16 -18 Because both oxLDLs and MMPs are present in atherosclerotic lesions and are able to trigger SMC proliferation, we investigated whether their mitogenic mechanisms were related. Because the MMP inhibitor batimastat inhibited the oxLDL-induced SMC proliferation, we investigated how MMPs mediate the oxLDL-induced mitogenic signaling. We report, for the first time, that the oxLDL-induced mitogenic signaling requires the activation of MT1-MMP and MMP-2, which in turn activates the Spm/Cer/S1P pathway.
Methods

SMC Culture
Rabbit femoral artery and human aortic SMCs (CRL 1999) (ATCC) were grown in RPMI-1640 supplemented with 10% FCS at 37°C, as described previously. 9 MMP-2-deficient fibroblasts from MMP-2 Ϫ/Ϫ mice 19 were grown in DMEM supplemented with 10% FCS. Twenty-four hours before each experiment, the medium was replaced with fresh RPMI medium containing 0.5% FCS.
Small-Interference RNA
MMP-2 expression was inhibited by small-interference RNA (siRNA) 5Ј-AGUUGGCAGUGCAAUACCUGA-3Ј (sense strand) (Dharmacon). SMCs were transfected with 20 mol/L double-strand siRNA in Optimem medium (Gibco) mixed with oligofectamine, as described previously. 20 Three hours after transfection, SMCs were incubated in RPMI containing 10% FCS for 24 hours. Then SMCs were incubated for 12 hours in RPMI containing 0.5% FCS before treatment with oxLDLs (100 g/mL). Alternatively, cells were treated with an irrelevant siRNA (p120 catenin siRNA) as negative control.
LDL Preparation and Oxidation
Human LDLs (1.019ϽdϽ1.063) were isolated from pooled fresh sera by sequential ultracentrifugation, dialyzed, sterilized by filtration, and oxidized by UV-C irradiation. 9
Evaluation of DNA Synthesis and Cell Proliferation
DNA synthesis was evaluated by [ 3 H]thymidine incorporation under the previously used conditions. 8 Alternatively, proliferating cells were detected by immunocytochemistry using anti-proliferating cell nuclear antigen (PCNA) antibody. Cells grown on uncoated glass coverslips, fixed in 3% paraformaldehyde for 15 minutes and permeabilized with 0.1% Triton X-100, were incubated with PCNA primary antibody for 30 minutes and with a secondary FITCconjugated anti-mouse IgG for 30 minutes and finally were examined by fluorescence microscopy.
Sphingolipid Quantification and Neutral Sphingomyelinase Determination
SMCs were prelabeled with [methyl-3 H]choline or [ 3 H]palmitic acid (0.5 Ci/mL), then were incubated with oxLDLs (100 g apolipoprotein B/mL) with or without MMP inhibitors, and radiolabeled sphingolipids were quantified as described previously. 9 Neutral sphingomyelinase activity was determined in cell extracts (100 g protein) in the presence of [choline-methyl- 14 C]sphingomyelin (120 000 dpm/assay) as reported. 8
Zymography and Determination of MMP Activity
Gelatinase activity of SMC culture media was assayed by zymography analysis according to Xu et al. 17 Briefly, culture media (concentrated 10 times on columns 10 to 300 kDa, Pall Gelman Laboratory) were run on 10% SDS-PAGE gel containing 1 mg/mL gelatin. The gel was washed twice in 2.5% Triton X-100 solution and 5 times with water and was incubated overnight at 37°C in developing buffer (Tris-HCl 50 mmol/L, pH 7.4, CaCl 2 10 mmol/L, ZnCl 2 5 mmol/L, and 0.05% Brij-35), then stained with 0.5% Coomassie blue and destained in a 5% methanol/7% acetic acid solution.
MMP activity was determined on concentrated SMC media by use of the DNP-pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH 2 fluorogenic substrate (Calbiochem-WWR) as described previously. 21 After overnight incubation (37°C), 1 mL Tris-HCl buffer, pH 7, was added, and the fluorescence was read (excitation and emission wavelengths, 280 and 360 nm, respectively).
Western Blots
Western blots were performed as described previously. 22
Statistical Analysis
Data are presented as meanϮSEM. Estimates of statistical significance were performed by ANOVA (Tukey test; SigmaStat software), values of PϽ0.05 being considered significant. 
Chemicals
Results
MMP Inhibitors Inhibit SMC Proliferation Induced by oxLDL
OxLDLs (100 g/mL) are mitogenic and induce both ERK1/ ERK2 activation and DNA synthesis (ie, [ 3 H]thymidine incorporation) ( Figure 1 ) in cultured rabbit and human SMCs. It may be noted that, under the conditions used (nontoxic concentrations of UV-oxLDLs), we observed a significant increase in SMC numbers after 7 days of cell culture. 6 The MMP inhibitors, 10 nmol/L batimastat or Ro28-2653, strongly inhibited MAPK activation and SMC proliferation induced by oxLDL. The same results were obtained by silencing MMP-2 with siRNA and in MMP-2 Ϫ/Ϫ fibroblasts (optimal mitogenic effect at 10 g/mL oxLDLs for fibroblasts) ( Figure 1 , D and E). In contrast, MMP inhibitors did not inhibit growth factor-induced DNA synthesis triggered by FCS (data not shown). OxLDLs induce MMP activation.
OxLDLs triggered an increase of MMP activity released in the SMC culture medium that peaked after 90 minutes of pulse ( Figure 2A ). No significant MMP activity was detected in cell-and serum-free medium, suggesting that oxLDL-activated MMPs originated from SMCs. SDS-PAGE zymography showed a rise of the gelatinolytic activity of 65-kDa after 1 hour of pulse with oxLDLs ( Figure 2B ), suggesting that oxLDLs trigger an early activation of MMP-2 in the culture medium. Both batimastat and Ro28-2653 inhibited this oxLDL-induced MMP activation. Note that the (1 hour) oxLDL-induced MMP activation in the culture medium did not require de novo protein synthesis, because cycloheximide was ineffective to block this activation (Table) and because the level of MT1-MMP and MMP-2 protein expression remained unchanged in SMCs treated for 1 hour with oxLDL ( Figure 2C ). This suggests that increased MMP-2 visualized by zymography in the culture medium probably results from the processing of pro-MMP-2 (see below).
Inhibition of MMP-2 Blocks the oxLDL-Induced Activation of the Sphingomyelin/Ceramide Pathway
As we previously described, oxLDL-induced SMC proliferation is mediated by the sphingomyelin/ceramide pathway. 8, 9 We investigated whether a link exists between MMP-2 activation and these signaling pathways activated by oxLDLs. The oxLDL-induced activation of the sphingomyelin/cer- amide pathway (ie, neutral sphingomyelinase activation, sphingomyelin hydrolysis, and ceramide generation) was inhibited by 10 nmol/L batimastat and was abolished in MMP-2-silenced cells (SMCs treated with siRNA) and in MMP-2 Ϫ/Ϫ fibroblasts (in contrast to MMP-2 ϩ/ϩ wild-type cells, which exhibited sphingomyelinase activation) ( Figure  3) . These data suggest that MMP-2 is implicated in the oxLDL-induced activation of the sphingomyelin/ceramide pathway.
Interestingly, the mitogenic effect of oxLDL was inhibited by anti-MMP-2 and anti-MT1-MMP blocking antibodies, as assessed by the inhibition of ERK1/2 activation, DNA synthesis, and nuclear translocation of PCNA (Figure 4 , A through C). This suggests that MMP-2 activation is mediated by MT1-MMP.
To confirm the role of MMP-2 and MT1-MMP, SMCs were treated by exogenous recombinant rMMP-2 and rMT1-MMP. As shown in Figure 4 , D through G, rMT1-MMP and rMMP-2 triggered the activation of the neutral sphingomyelinase, leading to sphingomyelin hydrolysis, ERK1/2 phos-phorylation, and DNA synthesis. These data strongly support the hypothesis that MT1-MMP and, subsequently, MMP-2 are able to activate the sphingomyelin/ceramide pathway. It may be noted that MMP-1 was unable to activate sphingomyelinase and DNA synthesis, thus suggesting that the effect of MMP-2 in cell signaling is not a trivial property of all the MMPs.
Together, these data suggest that the oxLDL-induced activation of the sphingomyelin/ceramide pathway involved in SMC proliferation is mediated by an MT1-MMP/MMP-2dependent mechanism.
MMPs Are Not Involved in the oxLDL-Induced Receptor Tyrosine Kinase Activation
Tyrosine kinase receptors (TKRs), such as EGFR and platelet-derived growth factor receptor (PDGFR), are activated by oxLDLs through adduct formation by lipid oxidation products and generation of reactive oxygen species. 22 For instance, PDGF stimulates SMC migration through mechanisms involving MMP-2 and MMP-9, 23 and a decreased MMP-2 expression is associated with PDGFR downregulation. 24 PDGFR and reactive oxygen species trigger MMP activation in various cellular systems and in animal models of atherosclerosis through mechanisms involving gene induction, mRNA stabilization, and pro-MMP activation. 11, 12 This led us to investigate whether a relationship exists between oxLDL-induced TKR signaling and MMPs.
Because batimastat did not inhibit PDGFR and EGFR activation induced by mitogenic concentrations of oxLDL (data not shown), it is suggested that the oxLDL-induced activation of the 2 TKRs did not require MMPs. Conversely, the EGFR and PDGFR inhibitors AG1478 and AG1295, which effectively blocked the oxLDL-dependent autophosphorylation of these TKRs, did not inhibit sphingomyelin hydrolysis or sphingomyelinase activation triggered by ox-LDLs (Table) . Conversely, EGF and PDGF did not trigger any sphingomyelinase activation under the experimental conditions used here (Table) . Together, MMPs are required for the oxLDL-induced activation of the sphingomyelin/ceramide pathway but not for the oxLDL-induced TKR (PDGFR and EGFR) activation.
Activity of MMPs in SMC Culture Medium and Sphingomyelinase in SMC Homogenates and Effect of Diverse Agonists
Discussion
MMPs play a complex role in vascular remodeling, because they are able to degrade the extracellular matrix and to promote SMC proliferation 11, 12 and may thereby participate in generating unstable plaques (in case of prominent proteolysis) or stenosis (in case of prominent SMC proliferation). 11, 12 Focal activation of MMP-2 may be elicited by partial proteolysis by thrombin or MT1-MMP in response to cytokines and oxLDLs. 25 MMP-2 may also induce cell proliferation of rat mesangial cells 25 and SMCs, 26, 27 but the mechanism of the mitogenic effect of MMPs is largely unknown.
In preliminary experiments, we observed that batimastat, a broad-specificity MMP inhibitor, inhibited the oxLDLinduced proliferation of SMCs. Because oxLDL-induced SMC proliferation involves 2 major mitogenic signaling pathways, the sphingomyelin/ceramide and the TKR/PI3K/ Akt pathways, 8, 9 we investigated whether MMPs were implicated in the activation of these pathways and subsequent SMC proliferation.
The first major finding is the crucial role that MMP-2 plays in the oxLDL-induced proliferation of rabbit and human SMCs, as assessed by the use MMP inhibitors (batimastat and Ro28-2653) and MMP-2-deficient cells. 28 In our experimental system, the mitogenic MMP was clearly identified as MMP-2 on the basis of zymography (65-kDa activated form), of the inhibitory effect of anti-MMP-2 antibodies, of anti-MMP-2 siRNA, and by the lack of mitogenic response in MMP-2 Ϫ/Ϫ fibroblasts. Interestingly, in our model system, in agreement with Kuzuya et al, 29 MMP-2 inhibitors did not reduce cell proliferation induced by PDGF and EGFR, thus suggesting that MMP-2 is not required for growth factorinduced growth factors.
This oxLDL-induced MMP-2 activation is mediated by MT1-MMP, as assessed by the effects of anti-MT1-MMP antibody and of exogenous rMT1-MMP. This is consistent with the general role of MT1-MMP in the proteolytic activation of pro-MMP-2. 30 The mechanism of MT1-MMP activation by oxLDLs is independent of any MT1-MMP overexpression and may result from a regulation of MT1-MMP activity by (1) clathrin-dependent endocytosis, 31 (2) activation of integrins, 32 and (3) serine proteases. 11, 13 This latter hypothesis is consistent with our previous results that show that TPCK, a synthetic serine protease inhibitor, efficiently inhibited oxLDL-induced MMP activation (data not shown), sphingomyelin/ceramide pathway activation, and SMC proliferation. 8 The second major finding is the role of MMP-2 in sphingomyelin/ceramide pathway activation. The precise molecular mechanism of regulation of the sphingomyelin/ceramide pathway remains poorly understood. 33 Our data strongly support a crucial role of MMP-2 in triggering sphingomyelinase activation, because Ro28-2653 (specific to MMP-2 and MMP-9), blocking anti-MMP-2 antibodies, and MMP-2 defect (MMP-2 Ϫ/Ϫ cells or cells depleted by anti-MMP-2 siRNA) inhibit sphingomyelinase activation, sphingomyelin hydrolysis, and ceramide production. This is also supported by the effect of exogenous MMP-2 (but not MMP-1), which triggered both the activation of the sphingomyelin/ceramide pathway and DNA synthesis. This suggests that the ability of MMP-2 to activate sphingomyelinase is not a trivial property of all MMPs. Our data suggest that MMP-2 may be a missing link between lipoproteins and the cell signaling machinery involved in SMC proliferation. 35 In conclusion, our data shed light on a novel cell signaling mechanism involved in oxLDL-induced SMC proliferation, in which MMP-2 plays a central role in the activation of the sphingomyelin/ceramide pathway and subsequent DNA synthesis ( Figure 5 ). Interestingly, MMP-2 is not implicated in cell proliferation induced by PDGF, in agreement with the observations of Kuzuya et al. 29 This suggests that the mechanism reported here might be of pathophysiological importance in atherosclerotic lesions in which oxLDLs are present 2,5,7 and in which MMP-2 is overexpressed. 11, 12 Finally, because the mechanism described here is triggered by exogenously added MMP-2, it might be of importance under conditions leading to high levels of activated MMP-2 in the vascular wall. [25] [26] [27] In addition to the well-known role of MMPs in extracellular matrix turnover and vascular remodeling, this novel role of MMP-2 in the regulation of the sphingomyelin/ceramide pathway may be of importance in various cellular responses, including proliferation, migration, and apoptosis. 34 -36 These cellular events may participate not only in intimal hyperplasia 29 but also in the formation of the atherosclerotic plaques.
From a pathophysiological point of view, our data provide a new mechanistic explanation and a molecular basis to the potential clinical use of MMP inhibitors to prevent excessive SMC proliferation such as observed in coronary artery disease, carotid stenosis, and peripheral artery disease. However, drugs that reduce SMC proliferation must be used cautiously, because a strong fibroproliferative cap may prevent the plaque instability and reduce the risk of atherothrombotic events. 
